Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский Nederlands Čeština Svenska Türkçe
GHK
Cu

GHK-Cu

Copper Peptide GHK-Cu

402.92 g/mol Molecular Weight
C14H23CuN6O4+ Formula
Clinical Studies Status
Gly-His-Lys-Cu
Updated on November 7, 2026
GHK-Cu Photo: Anna Keibalo
Peptide Serums: Does GHK-Cu Actually Work?English, subtitles FR · ES · DE · IT · PT

Overview

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a tripeptide naturally present in human blood plasma, saliva, and urine. Discovered in 1973 by Dr. Loren Pickart, this peptide complex has an exceptional affinity for copper (II) ions, forming a stable chelate that constitutes one of the main physiological copper transporters in the body.

The plasma concentration of GHK-Cu decreases significantly with age: from approximately 200 ng/mL at age 20, it drops to approximately 80 ng/mL around age 60. This decline correlates with the age-related slowdown of tissue regenerative capacities, which has directed research toward anti-aging and regenerative applications of this peptide.

GHK-Cu is one of the few bioactive peptides that has been the subject of clinical studies in the dermatological field. Its well-characterized safety profile and natural presence in the body make it a particularly interesting candidate for cosmetic formulations and applications in cutaneous regenerative medicine. GHK-Cu is a key component of blends such as Klow Peptide and Glow Peptide. For a detailed article on its anti-aging applications, see GHK-Cu: the anti-aging peptide.

Besides topical products, GHK-Cu is also sold in Europe as a pre-filled pen; see our guide to choosing between a vial and a pre-filled pen for a comparison of price per mg and stability.

Mechanism of Action

The mechanism of action of GHK-Cu relies on its ability to extensively modulate gene expression. Transcriptomic studies have revealed that this peptide influences the expression of more than 4,000 human genes, approximately 6% of the genome. Among the activated pathways are those involved in tissue repair, antioxidant defense (via superoxide dismutase and glutathione peroxidase), and synthesis of extracellular matrix components.

At the skin level, GHK-Cu stimulates the production of type I, III, and V collagen by dermal fibroblasts, as well as the synthesis of proteoglycans (decorin) and glycosaminoglycans. It also activates the production of matrix metalloproteinases (MMP-2) involved in tissue remodeling, while inhibiting excessive pro-inflammatory MMPs. This dual role promotes orderly matrix remodeling.

The copper ion plays an essential catalytic role in these processes. It serves as a cofactor for lysyl oxidase, a key enzyme in collagen and elastin cross-linking, and for mitochondrial cytochrome c oxidase, thereby supporting cellular energy metabolism. GHK-Cu also exerts anti-inflammatory effects by inhibiting the release of pro-inflammatory cytokines (IL-6, TNF-alpha) and by modulating the activity of the nuclear factor NF-kB.

Studied Benefits

Skin Regeneration and Anti-Aging

Controlled clinical studies have demonstrated that GHK-Cu improves dermal density and thickness, increases collagen and elastin production, and visibly reduces wrinkles and fine lines. The only comparative study we found is a small one-month pilot study on the thighs (Abdulghani et al., 1998): collagen production increased in more women with a GHK-Cu cream (70%) than with a vitamin C cream (50%) or tretinoin (40%), and retinol was not tested.

Wound Healing

GHK-Cu accelerates skin healing by stimulating angiogenesis, fibroblast migration, and collagen synthesis at the injury site. Clinical studies on chronic and post-surgical wounds have shown a significant reduction in healing time and an improvement in scar tissue quality.

Antioxidant Activity

GHK-Cu strengthens endogenous antioxidant defenses by increasing the expression of superoxide dismutase (SOD), glutathione peroxidase, and ferritin. This action reduces cellular oxidative damage induced by free radicals, UV radiation, and environmental pollutants.

Hair Growth Stimulation

Research has shown that GHK-Cu increases hair follicle size, stimulates follicle cell proliferation, and prolongs the anagen phase of the hair cycle. Comparative studies suggest efficacy comparable to 5% minoxidil in certain alopecia models.

Research Status

GHK-Cu benefits from a solid body of research spanning more than five decades, since its discovery in 1973. Studies have progressed from initial in vitro observations to controlled clinical trials, particularly in the dermatological field. Several randomized double-blind clinical trials have been published, evaluating the efficacy of GHK-Cu in topical creams for skin rejuvenation.

Transcriptomic studies conducted by the Pickart and Campbell team constituted a major breakthrough by revealing the extent of GHK-Cu's genomic action. This work, using DNA microarray technology (Connectivity Map), identified the signaling pathways modulated by the peptide, opening new therapeutic perspectives in the fields of pulmonary fibrosis, neurodegenerative diseases, and oncology.

The cosmetic applications of GHK-Cu are the best clinically validated, with several commercialized products containing this peptide. Current research focuses on regenerative medicine applications, including chronic wound healing, bone regeneration, and neuroprotection. Preclinical studies are also exploring its potential in the treatment of COPD and idiopathic pulmonary fibrosis.

Safety and Side Effects

GHK-Cu has a well-established safety profile, benefiting from a long history of use in cosmetic dermatology. Published clinical studies report excellent skin tolerance, with no significant irritation or notable allergic reactions at concentrations used in topical formulations (generally 0.01% to 1%). Repeated skin sensitization tests have not revealed any allergenic potential.

As a natural component of human plasma, GHK-Cu has an intrinsic advantage in terms of biocompatibility. In vitro cytotoxicity studies confirm the absence of cellular toxicity at physiological and supraphysiological concentrations. However, high concentrations of free copper could theoretically induce oxidative stress; the chelated GHK-Cu form minimizes this risk by ensuring controlled release of the copper ion.

Side effects reported in the literature are rare and generally mild, limited to transient redness or a slight tingling sensation upon topical application. No adverse systemic effects have been documented during topical use. For non-topical routes of administration, safety data remain more limited and require further investigation.

Regulatory status: cosmetic vs injectable

GHK-Cu falls under two very different sets of rules depending on how it is used: as an ingredient in creams and serums, or as an injectable product.

Cosmetic use (topical)

In the European Union, the ingredient name (INCI) Copper Tripeptide-1 is listed in CosIng, the European Commission database of cosmetic ingredients, with the function "skin conditioning" and no entry in the annexes of prohibited or restricted substances of Regulation (EC) No 1223/2009. CosIng is an information database, not an approval: the company that places a cosmetic on the market remains responsible for its safety assessment. In the United States, cosmetics do not need FDA approval before sale, but a product that claims to treat a disease or to change the structure or function of the body is regulated as a drug.

Injectable use

We found no approved medicine containing GHK-Cu in the United States or the European Union. On the FDA page listing bulk drug substances that may present significant safety risks in compounding (content current as of 22 April 2026), "GHK-Cu (for injectable routes of administration)" appears in the list of substances that were previously in category 2 and whose nomination was withdrawn. The FDA states there that compounded injectable drugs containing GHK-Cu may pose a risk of immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety considerations. This entry concerns injectable routes only; it says nothing about cosmetic creams.

The US HHS enforcement-discretion policy of 28 October 2026 on compounded peptides names six substances (BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV). GHK-Cu is not one of them, so that policy does not apply to it.

Vials sold online as "research use only" GHK-Cu are neither cosmetics nor medicines: no regulator checks their purity, copper content or sterility.

What the evidence does not show

  • Large, independent facial trials. The facial studies most often quoted (12-week studies in 67 and 71 women, summarized in reviews by Pickart and colleagues) were small, and several were presented at congresses or by manufacturers rather than published in full in peer-reviewed journals. A 2025 review of topical GHK noted "a surprising absence of clinical studies" with GHK-Cu and Pal-GHK, and a 2026 systematic evidence-mapping review judged the clinical evidence sparse; it also reports a 13-participant study after CO2 laser treatment that was negative on objective endpoints.
  • A controlled human trial of injected GHK-Cu. We found no published randomized trial of injected GHK-Cu in humans. The only registered phase 2 trial we found (NCT07437586, started in February 2026 and still recruiting) tests a topical gel on standardized skin wounds, not injections.
  • Proof that GHK-Cu "resets" thousands of genes in people. The figure of about 4,000 genes comes from analyses of the Broad Institute Connectivity Map: gene-expression profiles measured in cultured human cell lines exposed to GHK, then compared by computer with disease signatures (Campbell 2012; Pickart 2014). These are in vitro and in silico data, not measurements in the skin or blood of people using GHK-Cu.
  • Human confirmation of the preclinical leads. Results on lung fibrosis, nerve, bone and hair come mainly from cell and animal studies; none has been confirmed in a controlled human trial.
  • Long-term safety. Tolerance data concern topical creams used for weeks to months. There are no long-term human safety data for injected or other systemic use.

Recent research 2020-2026

Recent publications on GHK-Cu focus on three areas: getting the peptide through the skin, critical reviews of the evidence, and new preclinical models.

  • Skin delivery (2025). GHK-Cu is water-loving and charged, so it crosses intact skin poorly. A review in BioImpacts (Mortazavi et al.) concluded that GHK-Cu and Pal-GHK work well in cell studies and are relatively skin permeable, that permeation can be increased (microneedles, cell-penetrating peptides, lipid chains), and that clinical studies are surprisingly absent.
  • Critical evidence review (2026). A systematic evidence-mapping review in Pharmaceutics (Mateescu et al.) found consistent preclinical support for matrix remodeling, epithelial repair, anti-inflammatory and antioxidant effects, but concluded that clinical evidence remains sparse and that GHK-Cu should be regarded as a promising but unproven therapeutic agent. It also points out that many products and studies do not define which copper-peptide species they actually contain.
  • Lung fibrosis in mice (2024). In a mouse model of silicosis, GHK-Cu reduced lung inflammation and fibrosis, apparently by binding peroxiredoxin 6 and reducing oxidative stress in alveolar macrophages (Bian et al., Redox Biology). This is an animal result only.
  • First registered wound trial (2026). A randomized, double-blind, vehicle-controlled phase 2 trial of a topical GHK-Cu gel on standardized punch-biopsy wounds in healthy adults (NCT07437586, sponsor Hudson Biotech, about 60 participants planned) started in February 2026. No results are available yet.

Test your knowledge

Quick quiz · 6 questions

🏆

Where to buy this peptide?

We analyzed the best suppliers to help you find a quality, lab-tested product.

See our selection →

GHK-Cu: all our articles

Frequently Asked Questions

What is GHK-Cu and where is it found naturally?
GHK-Cu is a tripeptide (glycyl-histidyl-lysine) complexed with a copper (II) ion. It is naturally present in human blood plasma, saliva, and urine. Its plasma concentration decreases with age, dropping from approximately 200 ng/mL in young adults to 80 ng/mL in older individuals.
What are the proven benefits of GHK-Cu for the skin?
Controlled clinical trials have demonstrated that topically applied GHK-Cu improves skin firmness, reduces wrinkles, increases dermal thickness and density, and improves skin elasticity. In a small one-month pilot study on the thighs (Abdulghani et al., 1998), more women showed increased collagen production with a GHK-Cu cream (70%) than with a vitamin C cream (50%) or tretinoin (40%); we found no study comparing it with retinol on facial wrinkles.
Is GHK-Cu safe for cosmetic use?
Yes, GHK-Cu has a well-documented safety profile for topical cosmetic use. As a natural component of human plasma, it exhibits excellent biocompatibility. Clinical studies report very good skin tolerance, with rare and mild side effects (occasional transient redness).
How does GHK-Cu compare to other anti-aging peptides?
GHK-Cu stands out through its unique mechanism of action involving copper transport and modulation of more than 4,000 genes. Unlike Matrixyl, which primarily targets collagen synthesis, or Argireline, which acts on muscle contraction, GHK-Cu acts on a very broad spectrum of biological processes including tissue repair, antioxidant defense, and anti-inflammation.
At what concentration is GHK-Cu effective?
In clinical studies, GHK-Cu has shown efficacy at topical concentrations ranging from 0.01% to 1%. The optimal concentration depends on the formulation and vehicle used. Biological effects are observed at nanomolar concentrations in vitro, which demonstrates the potency of this signaling peptide.
Is GHK-Cu really better than retinol or vitamin C?
Current evidence does not show that. The claim comes from one small pilot study (Abdulghani et al., 1998) in which creams were applied to the thighs for one month: skin biopsies showed increased collagen production in 70% of women using a GHK-Cu cream, versus 50% with a vitamin C cream and 40% with tretinoin (retinoic acid). The study measured collagen, not wrinkles, and did not test retinol. We found no larger trial that repeated it, and no head-to-head facial trial against retinol.
What is the regulatory status of GHK-Cu?
As a cosmetic ingredient, copper tripeptide-1 is listed in the EU CosIng database (skin conditioning), and creams containing it are sold in the EU and the US. GHK-Cu is not an approved medicine. For injectable compounding, the FDA lists GHK-Cu among substances whose nomination was withdrawn, noting a possible immunogenicity risk and limited human data. The HHS policy of 28 October 2026 on six compounded peptides does not include GHK-Cu.

Scientific Sources

  1. Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015, 648108. (PubMed · DOI)
  2. Pickart L, Vasquez-Soltero JM, Margolina A. (2014). GHK and DNA: Resetting the human genome to health. BioMed research international, 2014, 151479. (PubMed)
  3. Arul V, Kartha R, Jayakumar R. (2007). A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sciences, 80(4), 275-284. (PubMed · DOI)
  4. Canapp SO, Farese JP, Schultz GS, et al. (2003). The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 32(6), 515-523. (PubMed)
  5. Finkley MB, Appa Y, Bhandarkar S. (2005). Copper peptide and skin. Cosmeceuticals and Active Cosmetics, 2nd Ed., CRC Press, 549-563. (DOI)
  6. Campbell JD, McDonough JE, Zeskind JE, et al. (2012). A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine, 4(8), 67. (PubMed · DOI)
  7. Abdulghani AA, Sherr A, Shirin S, et al. (1998). Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin: a pilot clinical, histologic, and ultrastructural study. Disease Management and Clinical Outcomes, 1(4), 136-141. (DOI)
  8. U.S. Food and Drug Administration (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (GHK-Cu for injectable routes: nominated but withdrawn; content current as of 22/04/2026). FDA, Human Drug Compounding. (fda.gov)
  9. European Commission (2026). CosIng cosmetic ingredient database: Copper Tripeptide-1 (substance ID 55687, function: skin conditioning). CosIng, European Commission. (ec.europa.eu)
  10. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. (2025). Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts, 15, 30071. (PubMed · DOI)
  11. Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. (2026). GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics, 18(9), 1077. (PubMed · DOI)
  12. Bian Y, Deng M, Liu J, et al. (2024). The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biology, 75, 103237. (PubMed · DOI)
  13. Hudson Biotech (2026). Topical GHK-Cu Gel for Acute Skin Wound Healing (CuHeal), phase 2, NCT07437586. ClinicalTrials.gov. (clinicaltrials.gov)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer

GHK-Cu
GHK-Cu
Powerful Anti-Aging →